|
Select Publications
Baselga J et al. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic
implications. Oncology 1997;11(3 Suppl 2):43-8. Abstract
Loesch D et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in
patients with advanced breast cancer. J Clin Oncol 2002;20:3857-64. Abstract
Pegram MD et al. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin
Oncol 2000;27(6 Suppl 11):21-5. Abstract
Pegram MD et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity
in human breast and ovarian cancer cells. Oncogene 1997;15(5):537-47. Abstract
Perez EA et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for
women with metastatic breast carcinoma. Cancer 2000;88:124-31. Abstract
Robert N et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus
trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An
update including survival. J Clin Oncol 2004;22(14 Suppl);Abstract 573.
Rowland KM et al. NCCTG 98-32-52:Randomized phase II trial of weekly versus every 3-week
administration of paclitaxel, carboplatin and trastuzumab in women with HER2 positive
metastatic breast cancer (MBC). Proc ASCO 2003;Abstract 31.
Seidman A et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21. Abstract
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone
for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of
the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update
analyses. Cancer 2003;98:1802-1810. Abstract
Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving
adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;82;Abstract 3.
Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen
therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of
tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802. Abstract
Jakesz R, on behalf of the ABCSG, the GABG. Benefits of switching postmenopausal women
with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen:
combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 trial.
Presentation. San Antonio Breast Cancer Symposium 2004. Abstract 2
Winer EP et al. American Society of Clinical Oncology technology assessment on the use of
aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive
breast cancer: Status report 2004. J Clin Oncol 2005;23(3):619-29. Abstract
Howell A, on behalf of the ATAC Trialists’ Group. The ATAC (‘Arimidex’, Tamoxifen, alone or in
Combination) trial in postmenopausal women with early breast cancer-updated efficacy results
based on a median follow of 5 years. Presentation. San Antonio Breast Cancer Symposium 2004.
Abstract
|
